Literature DB >> 25042220

Towards a cure for HIV--are we making progress?

Sharon R Lewin1, Steven G Deeks2, Françoise Barré-Sinoussi3.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25042220     DOI： 10.1016/S0140-6736(14)61181-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  12 in total

Review 1.  Global strategies are required to cure and eliminate HBV infection.

Authors:  Peter Revill; Barbara Testoni; Stephen Locarnini; Fabien Zoulim
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

2.  Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.

Authors:  Li Liu; Bhavik Patel; Mustafa H Ghanem; Virgilio Bundoc; Zhili Zheng; Richard A Morgan; Steven A Rosenberg; Barna Dey; Edward A Berger
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

Review 3.  Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection.

Authors:  Barna Dey; Edward A Berger
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

4.  Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency.

Authors:  Mykola Pinkevych; Christine M Fennessey; Deborah Cromer; Martin Tolstrup; Ole S Søgaard; Thomas A Rasmussen; Brandon F Keele; Miles P Davenport
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

5.  HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.

Authors:  Mykola Pinkevych; Deborah Cromer; Martin Tolstrup; Andrew J Grimm; David A Cooper; Sharon R Lewin; Ole S Søgaard; Thomas A Rasmussen; Stephen J Kent; Anthony D Kelleher; Miles P Davenport
Journal:  PLoS Pathog       Date:  2015-07-02       Impact factor: 6.823

Review 6.  Ending the HIV/AIDS epidemic in low- and middle-income countries by 2030: is it possible?

Authors:  Anthony D Harries; Amitabh B Suthar; Kudakwashe C Takarinda; Hannock Tweya; Nang Thu Thu Kyaw; Katie Tayler-Smith; Rony Zachariah
Journal:  F1000Res       Date:  2016-09-15

7.  Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC+ CD4+ cell levels: a surrogate marker candidate of HIV-induced intestinal damage.

Authors:  Mickaël J Ploquin; Armanda Casrouge; Yoann Madec; Nicolas Noël; Beatrice Jacquelin; Nicolas Huot; Darragh Duffy; Simon P Jochems; Luca Micci; Camille Lécuroux; Faroudy Boufassa; Thijs Booiman; Thalia Garcia-Tellez; Mathilde Ghislain; Roger Le Grand; Olivier Lambotte; Neeltje Kootstra; Laurence Meyer; Cecile Goujard; Mirko Paiardini; Matthew L Albert; Michaela Müller-Trutwin
Journal:  J Int AIDS Soc       Date:  2018-07       Impact factor: 5.396

8.  HEXIM1-Tat chimera inhibits HIV-1 replication.

Authors:  Marie Leoz; Petra Kukanja; Zeping Luo; Fang Huang; Daniele C Cary; B Matija Peterlin; Koh Fujinaga
Journal:  PLoS Pathog       Date:  2018-11-05       Impact factor: 6.823

Review 9.  Modeling Kick-Kill Strategies toward HIV Cure.

Authors:  Esteban A Hernandez-Vargas
Journal:  Front Immunol       Date:  2017-08-28       Impact factor: 7.561

10.  Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa.

Authors:  Andrew N Phillips; Valentina Cambiano; Paul Revill; Fumiyo Nakagawa; Jens D Lundgren; Loveleen Bansi-Matharu; Travor Mabugu; Mark Sculpher; Geoff Garnett; Silvija Staprans; Stephen Becker; Joseph Murungu; Sharon R Lewin; Steven G Deeks; Timothy B Hallett
Journal:  J Infect Dis       Date:  2016-03-30       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.